Pfizer to license COVID-19 antiviral was written by Michael McCoy. And the article was included in Chemical & Engineering News in 2021.Related Products of 2492423-29-5 The following contents are mentioned in the article:
A review. This article discusses about Pfizer to license COVID-19 antiviral. Pfizer will license its COVID-19 antiviral, PF-07321332, to the Medicines Patent Pool (MPP), which will make the drug available to generic-drug makers in low- and middle-income countries, assuming it is approved. Merck & Co. struck a similar deal with MPP in Oct. for its investigational antiviral, molnupiravir. Pfizer says lower-income countries will pay a not-forprofit price. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Related Products of 2492423-29-5).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran and dihydrofuran form the basic structural unit of many naturally occurring scaffolds like gambieric acid A and ciguatoxin, goniocin, and some biologically active molecules. Tetrahydrofuran can also be produced, or synthesised, via catalytic hydrogenation of furan. This process involves converting certain sugars into THF by digesting to furfural. An alternative to this method is the catalytic hydrogenation of furan with a nickel catalyst.Related Products of 2492423-29-5
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem